Immuno-oncology biotech Hookipa Pharma sets terms for $100 million IPO
Hookipa Pharma, a Phase 2 biotech developing T cell immunotherapies for various cancers, announced terms for its IPO on Monday.
The New York, NY-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. Insiders intend to purchase $40 million worth of shares in the offering (40% of the deal). At the midpoint of the proposed range, Hookipa Pharma would command a fully diluted market value of $412 million.
Hookipa Pharma was founded in 2011 and plans to list on the Nasdaq under the symbol HOOK. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of April 15, 2019.
The article Immuno-oncology biotech Hookipa Pharma sets terms for $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Latest IPOs Videos
- Bentley Systems prices IPO at $22, above the upwardly revised range
- US IPO Week Ahead: Palantir and Asana direct-list in 11 IPO week with tech, sports, and avocados
- Palantir moves NYSE direct listing date to September 29
- US IPO Week Ahead: The September IPO calendar stays Good(Rx) and busy in an 8 IPO week